Hutchin Hill Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Hutchin Hill Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-3,700	Closed	-$1.33M	–	688
2016 Q1	$1.33M	Sell	3,700 -2,300	-38%	-$948K	0.04%	367
2015 Q4	$3.26M	Buy	+6,000	New	+$3.25M	0.08%	231
2015 Q3	–	Sell	-800	Closed	-$408K	–	728
2015 Q2	$408K	Buy	+800	New	+$390K	0.01%	582
2014 Q3	–	Sell	-7,400	Closed	-$2.09M	–	696
2014 Q2	$2.09M	Buy	+7,400	New	+$2.19M	0.1%	144
2014 Q1	–	Sell	-4,200	Closed	-$1.16M	–	702
2013 Q4	$1.16M	Sell	4,200 -20,800	-83%	-$5.98M	0.08%	255
2013 Q3	$7.82M	Buy	25,000 +2,250	+10%	+$592K	0.71%	37
2013 Q2	$5.12M	Buy	+22,750	New	+$5.3M	0.53%	38

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Hutchin Hill Capital's REGN Position: Q2 2016 in Review

Hutchin Hill Capital sold out of Regeneron Pharmaceuticals (REGN) in Q2 2016, closing a stake of 3,700 shares — an estimated $1.33M sold.

Hutchin Hill Capital first reported a position in REGN in Q2 2013 and held it in 7 quarters. The position peaked at $7.82M in Q3 2013. 542 funds tracked by Wall St. Rank hold REGN as of Q2 2016.

Hutchin Hill Capital reported no remaining Regeneron Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Hutchin Hill Capital sold 3,700 Regeneron Pharmaceuticals shares in Q2 2016, an estimated $1.33M.
Hutchin Hill Capital first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Hutchin Hill Capital's Regeneron Pharmaceuticals position peaked at $7.82M in Q3 2013.
542 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2016.

Based on Hutchin Hill Capital's 13F filing for Q2 2016, filed 15 Aug 2016.